NetworkNewsBreaks – Biogen Inc. (NASDAQ: BIIB) Featured in Mizuho Securities Research Report
Biogen (NASDAQ: BIIB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Biogen announced that has exercised its option to develop and commercialize Genentech’s (a wholly-owned member of the Roche Group, RHHBY, not covered) CD20xCD3 T-cell engaging bispecific antibody mosunetuzumab (mosu). While Biogen already has certain presence in the oncology space through its anti-CD20 collaboration with Genentech, today’s announced exercised option builds upon this — and should be incrementally value accretive — with mosu bearing ~$1Bn risk-adjusted WW peak sales according to consensus (Biogen will get low-to-mid 30% of operating profits…







